Reversed isoniazids: Design, synthesis and evaluation against Mycobacterium tuberculosis
作者:Malkeet Kumar、Kawaljit Singh、Andile H. Ngwane、Fahreta Hamzabegovic、Getahun Abate、Bienyameen Baker、Ian Wiid、Daniel F. Hoft、Peter Ruminski、Kelly Chibale
DOI:10.1016/j.bmc.2017.12.047
日期:2018.2
Novel reversed isoniazid (RINH) agents were synthesized by covalently linking isoniazid with various efflux pump inhibitor (EPI) cores and their structural motifs. These RINH agents were then evaluated for anti-mycobacterial activity against sensitive, isoniazid mono-resistant and MDR clinical isolates of M. tuberculosis and a selected number of compounds were also tested ex vivo for intracellular
通过将异烟肼与各种外排泵抑制剂(EPI)核及其结构基序共价连接,合成了新型反向异烟肼(RINH)剂。这些RINH剂然后针对敏感,异烟肼单抗性和MDR临床分离株的抗分枝杆菌活性的评估结核分枝杆菌和所选择的一些化合物还测试了离体细胞内的活性以及在溴化乙锭(EB)测定外排泵抑制功效。针对的各种菌株一些化合物的效力的结核分枝杆菌(4A - ç,7和8 ;分枝杆菌H37Rv-MIC 99 ≤1.25μM,R5401-MIC 99≤2.5微米,X_61-MIC 99 ≤5微米)证明的逆转抗结核剂战略走向新的抗分枝杆菌剂的发展,解决耐药性的迅速增长的问题的可能性。此外,对于> 90%的通过抑制巨噬细胞活性1A - Ç和图3b(MIC 90 ≤13.42μM)和EB的抑制流出证明这些化合物是令人鼓舞的。